Following specialists treat Neuroendocrine Tumor. Help us improve our data based on your experience.
Specialty scores for Neuroendocrine Tumor
Source: In partnership with Genetic and Rare Diseases Information Center, funded by the National Center for Advancing Translational Sciences, and the National Human Genome Research Institute https://rarediseases.info.nih.gov/gard.
A carcinoid tumor is a rare, slow-growing cancer that usually starts in the lining of the digestive tract (appendix, stomach, small intestine, colon, rectum) or in the lungs but may occur elsewhere. Because carcinoid tumors grow slowly and don't produce symptoms in the early stages, affected individuals may have the tumor for years before being diagnosed. In later stages the tumor sometimes produces hormones that can cause carcinoid syndrome. The syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. Surgery is the main treatment for a carcinoid tumor. If it does not spread to other parts of the body, surgery can typically cure the cancer.
Date Modified: 2012-04-09T12:18:00
The cause of carcinoid tumors is unknown. However, there are some risk factors (none of which are avoidable) that may increase a person's risk of developing a carcinoid tumor. Although risk factors can influence the development of cancer, most do not directly cause cancer. People with several risk factors may never develop cancer, while others with no known risk factors do. Possible risk factors for carcinoid tumors include:
Date Modified: 2012-04-09T12:43:00
Treatment of carcinoid tumor depends on the location, size, and spread of the tumor. Typically, surgery is the first step and aims to remove as much of the tumor as possible. If any tumor remains following surgery, or if the tumor has spread to distant parts of the body (metastasized), medications such as octreotide, everolimus, or other chemotherapy drugs may be used to treat this condition.
Date Modified: 2014-10-23T19:23:00
Trade Name: Afinitor
Indication: Treatment of adult patients with progressive, well differentiated, nonfunctional,neuroendocrine tumors(NET) of gastrointestinal (GI) or lung origin, (excluding pancreatic) with unresectable, locally advanced or metastatic disease.
Trade Name: Netspot
Indication: For use after radiolabeling with Ga 68, with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
Trade Name: Sandostatin LAR
Indication: Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.